enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. How a new FDA-approved drug can — and can’t — help people ...

    www.aol.com/fda-approved-drug-t-help-121600044.html

    In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...

  3. A Revolutionary New Alzheimer’s Drug Was Just Approved by the ...

    www.aol.com/revolutionary-alzheimer-drug-just...

    Lecanemab (a.k.a. leqembi) has received full approval from the U.S. Food and Drug Administration. This is the first FDA-approved treatment to help slow the progression of Alzheimer’s disease.

  4. Aducanumab - Wikipedia

    en.wikipedia.org/wiki/Aducanumab

    Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

  5. Who is eligible for the new FDA-approved Alzheimer's drug? - AOL

    www.aol.com/lifestyle/explainer-eligible-fda...

    Because it is a disease of aging, most Alzheimer's patients are covered by Medicare, which had effectively denied coverage of Leqembi under the accelerated approval it received in January. The ...

  6. Brexpiprazole - Wikipedia

    en.wikipedia.org/wiki/Brexpiprazole

    Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. [11] [13] [14] The most common side effects include akathisia (a constant urge to move) and weight gain. [12]

  7. William K. Summers - Wikipedia

    en.wikipedia.org/wiki/William_K._Summers

    On March 28, 1989 U.S. Patent 4,816,456 was issued to Dr. Summers. With no findings to support allegations and concerns, Frances Oldham Kelsey closed the FDA Office of Compliance investigation, in May, 1989. Nevertheless, the Office for Drug Evaluation I, placed Summers on a secret "black list" without informing him. [27]

  8. FDA approves a second Alzheimer's drug that can ... - AOL

    www.aol.com/news/fda-approves-second-alzheimers...

    U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

  9. Nicergoline - Wikipedia

    en.wikipedia.org/wiki/Nicergoline

    Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia.